Seres Therapeutics (NASDAQ:MCRB) Cut to Underweight at JPMorgan Chase & Co.

Seres Therapeutics (NASDAQ:MCRB) was downgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued to investors on Thursday, Marketbeat reports.

Several other equities research analysts have also recently weighed in on the company. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Friday, September 13th. Finally, Chardan Capital restated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, August 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Seres Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Price Performance

MCRB opened at $0.70 on Thursday. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05. The company’s 50 day moving average price is $0.89 and its two-hundred day moving average price is $0.91. The firm has a market capitalization of $119.97 million, a price-to-earnings ratio of -0.60 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. During the same quarter last year, the business posted $0.36 EPS. As a group, equities research analysts predict that Seres Therapeutics will post -0.95 EPS for the current year.

Insider Activity

In related news, insider Teresa L. Young sold 24,480 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.08, for a total transaction of $26,438.40. Following the completion of the sale, the insider now owns 78,178 shares of the company’s stock, valued at $84,432.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 28,844 shares of company stock valued at $30,104 in the last ninety days. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Seres Therapeutics in the first quarter valued at $39,000. Providence Wealth Advisors LLC raised its stake in Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after buying an additional 25,250 shares during the period. Point72 DIFC Ltd bought a new position in Seres Therapeutics in the second quarter worth approximately $64,000. Virtu Financial LLC bought a new position in Seres Therapeutics in the first quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.